Acceptance Des Maladies Chroniques Dermatologiques Visibles : Constitution d'échelles Pour le Patient et Son Cluster Familial

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Observational
SUMMARY

The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients (children, adolescents, adults) and their parents (depending on the composition of the family cluster), in a multicentric manner (for territorial representativeness).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
View:

• Targeted pathologies:

‣ Flat angioma

⁃ Primary hypopigmentation and early vitiligo

⁃ Primary hyperpigmentation

⁃ Refractory alopecia areata or congenital alopecia

• Persons concerned:

‣ Children (≥ 6 years old) suffering from one of the aforementioned pathologies

⁃ Adults suffering from one of the above-mentioned pathologies

⁃ Parents of children suffering from one of the aforementioned pathologies

⁃ Parents of young adult patients if they live under the same roof

• Oral agreement for each person (major/minor) and, where applicable, one of the holders of parental authority (minor)

Locations
Other Locations
France
University Hospital TOURS
RECRUITING
Tours
Contact Information
Primary
Annabel MARUANI, MD-PhD
annabel.maruani@univ-tours.fr
+33 (0)247479076
Time Frame
Start Date: 2022-01-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 250
Treatments
Children aged 6-13 years
Children aged 6-13 years with a chronic skin visible disease
Adolescents aged 14-17 years
Adolescents aged 14-17 years years with a chronic skin visible disease
Adult patients
Adult patients aged 18 years and more with a chronic skin visible disease
Parents of children aged 6 years and more
Parents of children aged 6 years and more with a chronic skin visible disease
Sponsors
Collaborators: INSERM UMR 1246 SPHERE
Leads: University Hospital, Tours

This content was sourced from clinicaltrials.gov